Home Dr. Yongliang Fang, COO of Doer Biologics, Named Zhejiang Province's Outstanding Engineer 2024 Amid IPO Filing

Dr. Yongliang Fang, COO of Doer Biologics, Named Zhejiang Province's Outstanding Engineer 2024 Amid IPO Filing

Aug 20, 2025 17:37 CST Updated 17:37
Doer Biologics

Biological Drug Developer

Recently,Zhejiang Provincial Department of Economy and InformatizationPublishedThe List of "Zhejiang Province Outstanding Engineers" for 2024: Dr. Yongliang Fang, COO of Doer Biologics, Successfully Selected.

Image

"Outstanding Engineer of Zhejiang Province" is a high-end precision industry talent in the economic and information field that Zhejiang Province focuses on supporting.Dr. Yongliang FangEntryThe selection is an authoritative recognition of its outstanding contributions and innovative practices in the field of biomedical engineering, and a high affirmation of Doer Biologics' technological innovation system and independent R&D capabilities.

As a young leader in the biopharmaceutical fieldMilitaryTalentDr. Fang YongliangBiologicsHe has accumulated profound experience in drug research and development, clinical translation, and business development. He leads his team to vigorously promote the clinical pipeline of the company's innovative drug research and development.Transformation, currently availableFive innovative drugs have entered different clinical stages, covering major and cutting-edge therapeutic areas such as oncology and metabolic diseases.

In the future, Doer Biologics will continue to address unmet clinical needs, accelerating the research, development, and industrialization of innovative biopharmaceuticals, contributing to China's self-innovative biopharmaceutical industry."Doer" Power!

About Doer Biologics

Zhejiang Doer Biologics Co., Ltd. ("Doer Biologics") is a clinical-stage biopharmaceutical company focused on discovering and developing multi-specific biotherapeutics based on multi-domain structures to address unmet medical needs in the fields of metabolic diseases and cancer.

Doer Biologics has developed a variety of proprietary platform technologies, includingxLONGylation®, MultipleBody®, AccuBody®, and SMART-VHHBody.

For more information about Doer Biologics, please visitwww.doerbio.com。